News Releases

Media Contact: Lissa Pavluk media@apellis.com (617) 977-6764

November 15, 2021 Apellis Pharmaceuticals Announces Proposed Public Offering of Common Stock
November 12, 2021 Apellis Reiterates Plans to Submit a New Drug Application in the First Half of 2022 for Pegcetacoplan for Geographic Atrophy Following FDA Feedback
November 10, 2021 Apellis Announces Three Oral Presentations of the Phase 3 DERBY and OAKS Data in Geographic Atrophy (GA) to be Highlighted at the AAO Annual Meeting
November 8, 2021 Apellis Pharmaceuticals Reports Third Quarter 2021 Financial Results
November 4, 2021 Apellis to Present New Data Reinforcing EMPAVELI™ (pegcetacoplan) Efficacy and Safety in Patients with PNH at the 2021 ASH Annual Meeting
November 3, 2021 Apellis Pharmaceuticals to Present at Upcoming Investor Conferences
November 1, 2021 Apellis Pharmaceuticals to Host Conference Call on November 8, 2021 to Discuss Third Quarter 2021 Financial Results
October 15, 2021 Apellis and Sobi Receive Positive CHMP Opinion for Aspaveli® (pegcetacoplan) for the Treatment of PNH
September 30, 2021 Apellis Announces Detailed Results from Phase 3 DERBY and OAKS Studies Presented at Retina Society Annual Meeting
September 20, 2021 Apellis Pharmaceuticals to Present at the 2021 Cantor Virtual Global Healthcare Conference